Skip to main content
Ambu logo

Ambu — Investor Relations & Filings

Ticker · AMBU ISIN · DK0060946788 LEI · 5299008W2A69WX355710 CO Manufacturing
Open in API
Filings indexed 1,332 across all filing types
Latest filing 2019-06-18 Director's Dealing
Country DK Denmark
Listing CO AMBU

About Ambu

https://www.ambu.com

Ambu is a global medical technology company that develops, manufactures, and markets single-use medical devices. A pioneer and market leader in single-use endoscopy, the company provides a broad portfolio of solutions for healthcare professionals across various clinical areas, including endoscopy, anesthesia, and patient monitoring. Its key products include the aScope™ line of single-use flexible endoscopes for pulmonology, gastroenterology, and urology, as well as video laryngoscopes. Ambu's solutions are designed to improve patient safety by eliminating the risk of cross-contamination associated with reusable devices, while also enhancing workflow efficiency in clinical environments by ensuring sterile, high-quality equipment is always available.

Recent filings

Filing Released Lang Actions
Director's Dealing 2019
Director's Dealing Classification · 99% confidence The document title is "Ambu A/S: Ledende medarbejders handler" which translates to "Ambu A/S: Transactions by leading employees". The text explicitly mentions a board member, Oliver Johansen, buying shares ('køber aktier'). This directly relates to insider trading or transactions by directors/executives. This aligns perfectly with the definition of Director's Dealing (DIRS). The document is very short and points to an attached filing, but the core content is the director's transaction, making DIRS more specific than RPA or RNS.
2019-06-18 Danish
Ambu A/S: Review of the Big Five 2020 Strategy
Earnings Release Classification · 95% confidence The document is a 'Selskabsmeddelelse' (Company Announcement) from Ambu, numbered 12 2018/19. It details a strategic update ('Big Five 2020'), changes to product portfolios, and a revision of financial guidance for the fiscal years 2018/19 and 2019/20. Because it is an official regulatory announcement regarding financial guidance and strategic shifts, it falls under the category of an Earnings Release/Financial Update announcement. While it contains detailed information, it is structured as a formal corporate announcement rather than a full quarterly report or a standalone presentation. Q3 2019
2019-06-17 Danish
Ambu A/S: Review of the Big Five 2020 Strategy
Earnings Release Classification · 95% confidence The document is a 'Company announcement' (no. 12 2018/19) from Ambu, which details a strategic review, product pipeline updates, and adjustments to financial guidance. While it contains financial outlook information, it is an initial announcement of these changes rather than a full quarterly or annual report. It fits the definition of an Earnings Release (ER) or a general regulatory announcement (RNS). Given the specific focus on financial outlook adjustments and strategic updates, it is best classified as an Earnings Release (ER). FY 2019
2019-06-17 English
Investor Presentation 2019
Investor Presentation Classification · 95% confidence The document is titled 'Ambu A/S: Review of the Big Five 2020 Strategy' and details strategic updates, product pipeline revisions, accelerated investments, and adjustments to the financial outlook for 2018/19 and 2019/20. This content strongly suggests a comprehensive update on business performance, strategy, and financial guidance, which aligns best with an Investor Presentation (IP) or a Management Discussion and Analysis (MDA). Since it provides detailed strategic rationale (discontinuing SC210, accelerating commercial infrastructure) alongside specific financial outlook adjustments (EBIT margin, growth targets), it functions as both an update presentation and management commentary. However, the document concludes by announcing a 'conference call' and an 'investor meeting' where the presentation can be downloaded, and it includes an attachment link. This structure—a detailed strategic narrative followed by logistics for a presentation/call—is highly characteristic of an Investor Presentation (IP) designed to accompany an earnings release or strategic update, rather than the full, formal MDA section of a 10-K or IR. Given the focus on strategy review, product pipeline, and forward-looking financial guidance presented in a narrative format intended for investors, 'Investor Presentation' (IP) is the most appropriate classification. It is not a short announcement (RPA/RNS) because the text length is substantial (over 10,000 characters) and contains the core information, not just a pointer to it.
2019-06-17 English
Management Reports 2019
Management Reports Classification · 99% confidence The document is a detailed announcement from Ambu A/S regarding the review and update of its 'Big Five 2020' strategy. It discusses product pipeline updates (aScope 5, new monitor platform, discontinuation of SC210), increased investment in the sales organization, and crucially, provides revised financial expectations for the current fiscal year (2018/19) and the next fiscal year (2019/20). This content—a comprehensive update on strategy, operations, and forward-looking financial guidance—is characteristic of an Earnings Release (ER) or a Management Discussion & Analysis (MDA). Since it provides detailed financial outlook adjustments and strategic rationale, it goes beyond a simple 'key highlights only' ER. However, it is not a full, audited report (10-K or IR). The text explicitly details management's explanation of business trends and outlook adjustments. Furthermore, it announces a teleconference and an investor meeting to discuss these results. This aligns best with the definition of Management Reports (MDA), which covers detailed explanations of financial results, business trends, and outlook, often released concurrently with or shortly after an Earnings Release.
2019-06-17 Danish
Ambu A/S: Cook Medical and Ambu announce collaboration to address endoscope-related infections
Regulatory Filings Classification · 95% confidence The document is a corporate announcement (Selskabsmeddelelse nr. 11 2018/19) regarding a strategic partnership between Ambu A/S and Cook Medical. It details the nature of the collaboration, the product involved (disposable duodenoscope), and the expected impact on financial guidance. Since it is a general corporate announcement that does not fit into specific categories like M&A (which usually implies a takeover or merger of entities) or financial reporting, it is classified as a general regulatory filing.
2019-05-18 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.